Affiliation:
1. Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
2. Department of Obstetrics and Gynecology, Hannover Medical School, 30625 Hannover, Germany
3. Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Abstract
Cervical cancer is one of the most common malignancies in women, and the majority of cases are caused by infection with high-risk human papilloma virus (HPV) subtypes. Despite effective preventative measures, such as vaccinations against HPV, over 300,000 women die world-wide from cervical cancer each year. Once cervical cancer is diagnosed, treatment may consist of radial hysterectomy, or chemotherapy and radiotherapy, or a combination of therapies dependent upon the disease stage. Unfortunately, overall prognosis for patients with metastatic or recurrent disease remains poor. In these cases, immunotherapies may be useful based on promising preclinical work, some of which has been successfully translated to the clinic. For example, approaches using monoclonal antibodies directed against surface proteins important for control of immune checkpoints (i.e., immune checkpoint inhibitors) were shown to improve outcome in many cancer settings, including cervical cancer. Additionally, initial clinical studies showed that application of cytotoxic immune cells modified to express chimeric antigen receptors (CAR) or T cell receptors (TCR) for better recognition and elimination of tumor cells may be useful to control cervical cancer. This review explores these important topics, including strengths and limitations of standard and developing approaches, and how some novel treatment strategies may be optimally used to offer the best possible treatment for cervical cancer patients.
Funder
Comprehensive Cancer Center Niedersachsen
Bruno and Helene Jöster Foundation
German Research Foundation
Federal Ministry of Education and Research
REBIRTH Center for Translational Regenerative Medicine
Reference178 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA;Sung;Cancer J. Clin.,2021
2. (2022, December 29). The American Cancer Society Cancer.org. 1.800.227.2345. Available online: https://www.cancer.org/content/dam/CRC/PDF/Public/8893.00.pdf.
3. Gasparini, R., and Panatto, D. (2009). Cervical cancer: From Hippocrates through Rigoni-Stern to zur Hausen. Vaccine, 27.
4. A note from history: Landmarks in history of cancer, part 1;Hajdu;Cancer,2011
5. The extended abdominal operation for carcinoma uteri (based on 500 operative cases);Wertheim;Am. J. Obstet. Dis. Women Child.,1912
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献